163 related articles for article (PubMed ID: 34431664)
1. 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Dolbois A; Bedi RK; Bochenkova E; Müller A; Moroz-Omori EV; Huang D; Caflisch A
J Med Chem; 2021 Sep; 64(17):12738-12760. PubMed ID: 34431664
[No Abstract] [Full Text] [Related]
2. Proteolysis Targeting Chimera Degraders of the METTL3-14 m
Errani F; Invernizzi A; Herok M; Bochenkova E; Stamm F; Corbeski I; Romanucci V; Di Fabio G; Zálešák F; Caflisch A
JACS Au; 2024 Feb; 4(2):713-729. PubMed ID: 38425900
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.
Yankova E; Blackaby W; Albertella M; Rak J; De Braekeleer E; Tsagkogeorga G; Pilka ES; Aspris D; Leggate D; Hendrick AG; Webster NA; Andrews B; Fosbeary R; Guest P; Irigoyen N; Eleftheriou M; Gozdecka M; Dias JML; Bannister AJ; Vick B; Jeremias I; Vassiliou GS; Rausch O; Tzelepis K; Kouzarides T
Nature; 2021 May; 593(7860):597-601. PubMed ID: 33902106
[TBL] [Abstract][Full Text] [Related]
4. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy.
Xu P; Ge R
Eur J Med Chem; 2022 Feb; 230():114118. PubMed ID: 35063732
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of Inhibitors of the m
Bedi RK; Huang D; Li Y; Caflisch A
ACS Bio Med Chem Au; 2023 Aug; 3(4):359-370. PubMed ID: 37599794
[TBL] [Abstract][Full Text] [Related]
6. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes.
Moroz-Omori EV; Huang D; Kumar Bedi R; Cheriyamkunnel SJ; Bochenkova E; Dolbois A; Rzeczkowski MD; Li Y; Wiedmer L; Caflisch A
ChemMedChem; 2021 Oct; 16(19):3035-3043. PubMed ID: 34237194
[TBL] [Abstract][Full Text] [Related]
7. Roles of METTL3 in cancer: mechanisms and therapeutic targeting.
Zeng C; Huang W; Li Y; Weng H
J Hematol Oncol; 2020 Aug; 13(1):117. PubMed ID: 32854717
[TBL] [Abstract][Full Text] [Related]
8. Discovery of substituted indole derivatives as allosteric inhibitors of m
Lee JH; Kim S; Jin MS; Kim YC
Drug Dev Res; 2022 May; 83(3):783-799. PubMed ID: 35040501
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of a Potent and Selective YTHDC1 Ligand.
Zálešák F; Nai F; Herok M; Bochenkova E; Bedi RK; Li Y; Errani F; Caflisch A
J Med Chem; 2024 Jun; 67(11):9516-9535. PubMed ID: 38787793
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer.
Bedi RK; Huang D; Eberle SA; Wiedmer L; Śledź P; Caflisch A
ChemMedChem; 2020 May; 15(9):744-748. PubMed ID: 32159918
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases.
Wang P; Doxtader KA; Nam Y
Mol Cell; 2016 Jul; 63(2):306-317. PubMed ID: 27373337
[TBL] [Abstract][Full Text] [Related]
13. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex.
Wang X; Feng J; Xue Y; Guan Z; Zhang D; Liu Z; Gong Z; Wang Q; Huang J; Tang C; Zou T; Yin P
Nature; 2016 Jun; 534(7608):575-8. PubMed ID: 27281194
[TBL] [Abstract][Full Text] [Related]
15. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
17. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
18. Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT).
Judd WR; Slattum PM; Hoang KC; Bhoite L; Valppu L; Alberts G; Brown B; Roth B; Ostanin K; Huang L; Wettstein D; Richards B; Willardsen JA
J Med Chem; 2011 Jul; 54(14):5031-47. PubMed ID: 21661760
[TBL] [Abstract][Full Text] [Related]
19. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
[TBL] [Abstract][Full Text] [Related]
20. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
